Binah Capital Group Inc. (BCG) Stock Price

1.10 ▼ -0.01 (-0.90%)
Open: 1.10 Vol: 6.14K Day's range: 1.0871 - 1.135 Nov 09, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
BCG Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL NEUTRAL NEUTRAL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 1.13▼ 1.12▼ 1.12▼ 1.11▼ 1.08▲
MA10 1.11▼ 1.11▼ 1.12▼ 1.09▲ 1.11▼
MA20 1.11▼ 1.10▲ 1.09▲ 1.07▲ 1.27▼
MA50 1.07▲ 1.07▲ 1.08▲ 1.14▼ 1.76▼
MA100 1.09▲ 1.14▼ 1.16▼ 1.31▼ 1.94▼
MA200 1.17▼ 1.25▼ 1.29▼ 1.66▼ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD -0.002▼ 0.000▲ 0.003▲ 0.012▲ 0.008▲
RSI 51.487▲ 51.764▲ 51.729▲ 49.929▼ 37.226▼
STOCH 44.537     38.611     41.591     39.596     25.541    
WILL %R -75.000▼ -68.182     -68.182     -65.282     -78.571▼
CCI -44.898     -25.796     -13.333     37.516     -48.815    
Latest Filters Detected On BCG
RSI $BCG RSI(14) Crossed Below 50 Set Alert
CDL $BCG Doji Candlestick Pattern Detected Set Alert
Binah Capital Group Inc. News
ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
Monday, November 09, 2026 04:03 AM
( NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted approval for ANKTIVA® (nogapendekin alfa ...
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
Monday, November 09, 2026 03:32 AM
( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 ( NCT02138734), a randomized, ...
ImmunityBio's ANKTIVA plus BCG meets goal in bladder cancer trial
Monday, November 09, 2026 03:31 AM
ImmunityBio, Inc. (NASDAQ: IBRX) announced that its drug combination of ANKTIVA plus BCG met the primary efficacy endpoint in a randomized, controlled registrational trial for BCG-naïve ...
BCG historical stock data
date open high low close volume
09/11/26 1.10 1.135 1.0871 1.10 6,135
06/11/26 1.13 1.15 1.09 1.11 6,239
05/11/26 1.21 1.21 1.06 1.10 16,277
04/11/26 1.11 1.18 1.11 1.16 11,600
03/11/26 1.06 1.08 1.06 1.06 4,556
02/11/26 1.08 1.125 1.06 1.09 28,079
30/10/26 1.11 1.1484 1.0601 1.08 16,737
29/10/26 1.07 1.17 1.07 1.08 13,474
28/10/26 1.06 1.0879 1.0501 1.0509 4,430
27/10/26 1.07 1.10 1.07 1.08 4,156
Quote Details
52wk Low:0.95
52wk High:3.44
Vol:6.14K
Avg Vol(3m):313.6K
1Y Chng:-64.63%
1M Chng:-3.93%
Add to Watch List
More Information
Index US Composite
Market Cap. 18.94M